The analysis of LVEF and first heart failure hospitalization in patients with T2DM treated with SGLT2 inhibitors reveals that empagliflozin is not only effective in improving glycemic control, weight, and blood pressure, but also demonstrates preventive potential in heart failure progression, even in patients without documented high cardiovascular risk. Here, SLC5A2 is linked to heart failure.